Eversense® Non-adjunctive Use Post Approval Study

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 925 participants.

Also called NCT04836546

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose other
Phase
Not applicable
Enrolled
  • 925 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04836546
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT04836546. Allocation not applicable; no masking; primary purpose other. Start 2021-04-13 (actual); primary completion 2026-03-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Eversense® Non-adjunctive Use Post Approval Study
Acronym
NA-PAS
Condition
Diabetes
Intervention (Device)
Blood glucose meter
Intervention (Device)
Eversense CGM System
Lead sponsor
Senseonics, Inc. (class: industry)

Record details

Record id
cardio:ct-nct04836546
Content hash
3b59c8f6652276e3bb22c79aca8f282052dc7dfced0d1e2ac631a3a1320c3f78